NIH Panel Provides Final COVID-19 Treatment Recommendations
Future updates to COVID-19 treatment recommendations will transition to professional medical societies.
Tag: remdesivir Veklury
All
Latest
NIH Panel Provides Final COVID-19 Treatment Recommendations
Future updates to COVID-19 treatment recommendations will transition to professional medical societies.
Read More
Veklury Recalled Due to Risk of Glass Particle Contamination
Gilead has recalled one lot of Veklury (remdesivir) after confirming the presence of a glass particle in a vial following a customer complaint.
Read More
WHO Updates Non-severe COVID-19 Treatment Guidance
The World Health Organization updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19.
Read More
Anti-inflammatory Drugs Didn’t Speed COVID-19 Recovery
New research reveals that three anti-inflammatory drugs showed no benefit in shortening recovery time in patients hospitalized with severe COVID-19, but two improved mortality rates.
Read More
Remdesivir Reduced COVID-19 Mortality, Hospital Readmission Rates Across All Variants
One analysis found that early administration of remdesivir in vulnerable patient populations resulted in an overall 25% lower risk of mortality at day 28 across all variant time periods.
Read MoreFDA Expands Approval of Remdesivir for Pediatric Patients
The US FDA expanded the approval of remdesivir (Veklury, Gilead Sciences) to include pediatric patients 28 days of age and older weighing at least 3 kg with positive results of direct SARS-CoV-2 viral testing.
Read More
Hyperimmune Intravenous Immunoglobulin Does Not Improve COVID-19 Outcomes
The combination of remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2 is not superior to remdesivir alone for treating adults hospitalized with COVID-19.
Read MoreFDA Expands Remdesivir Access for Mild-to-Moderate COVID-19 Outpatients
The US FDA took two actions to expand the use of the antiviral drug remdesivir (Veklury, Gilead Sciences Inc) to certain non-hospitalized adults and pediatric patients for the treatment of mild-to-moderate COVID-19.
Read MoreRemdesivir Reduced Hospitalization Risk, Mortality
Participants receiving a three-day course of remdesivir (Veklury, Gilead Sciences) had an 87% reduction in risk of COVID-19-related hospitalization or all-cause death by Day 28 and an 81% reduction in the risk of COVID-19-related medical visits or all-cause death by Day 28 compared to placebo.
Read More
Experimental Therapy for Parasitic Heart Disease May Also Help Stop COVID-19
By blocking human enzyme cathepsin L, chemical inhibitor K777 reduces coronavirus’ ability to infect cell lines, new research shows.
Read More
FDA Warns Against Remdesivir Compounds
The FDA is alerting healthcare professionals and compounders of potential risks associated with compounding remdesivir drug products.
Read MoreStudy: Remdesivir Disrupts COVID-19 Virus Better Than Similar Drugs
Using advanced computational simulations, researchers have revealed how the drug works at the molecular level.
Read More
NIH Updates COVID-19 Treatment Guidelines with Recommendations on Baricitinib
The NIH updated its COVID-19 Treatment Guidelines with new information following the FDA emergency use authorization of baricitinib.
Read MoreBaricitinib Plus Remdesivir Shows Promise for Treating COVID-19
The combination of baricitinib, an anti-inflammatory drug, and remdesivir reduced time to recovery for people hospitalized with COVID-19.
Read MoreCOVID-19 Trial to Compare Dexamethasone + Remdesivir versus Baricitinib + Remdesivir
The NIAID is enrolling participants in its ACTT-4 clinical trial to assess the effectiveness of dexamethasone plus remdesivir, compared to baricitinib plus remdesivir.
Read MoreBaricitinib-Remdesivir Combo Authorized to Treat COVID-19
The FDA issued an EUA for the drug baricitinib in combination with remdesivir to treat patients age two and older who are hospitalized COVID-19.
Read MoreRemdesivir First Therapeutic Approved by FDA for COVID-19
The US FDA approved the COVID-19 antiviral drug remdesivir (Veklury, Gilead Sciences) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kg.
Read More
Remdesivir Study Finally Published – An Expert in Critical Care Medicine Gives us His Verdict
The results of the ACTT-1 trial, which looked at the effectiveness of remdesivir as a treatment for COVID-19, have been published.
Read More
FDA Expands Authorization for Remdesivir to Treat All Hospitalized COVID-19 Patients
Remdesivir (trade name Veklury) is now authorized to treat all hospitalized adult and pediatric patients with suspected or laboratory-confirmed COVID-19, irrespective of their severity of disease.
Read More
COVID-19: Clinical Trial Starts for Remdesivir plus Interferon β1a
The National Institutes of Health has initiated a randomized, controlled clinical trial evaluating the safety and efficacy of the antiviral remdesivir (Gilead Sciences) plus the immunomodulator interferon beta-1a (Merck) in patients with COVID-19.
Read More
Gilead Puts Multiple Price Tags on COVID-19 Therapeutic Remdesivir
Gilead announced Remdesivir drug prices vary based on US insurance coverage. Generics are also being manufactured for developing nations.
Read More
India OK’s Generic Remdesivir for COVID-19
India has approved the manufacturing and marketing of a generic version of Gilead Sciences’ COVID-19 treatment remdesivir, Reuters reports.
Read More
New FDA Guidance for Remdesivir Use in COVID-19 Patients
The FDA says co-administration of remdesivir and chloroquine phosphate or hydroxychloroquine sulfate is not recommended as it may result in reduced antiviral activity of remdesivir.
Read More
Remdesivir Improved Time to Recovery in COVID-19 Patients
Remdesivir was most beneficial for hospitalized COVID-19 patients with severe disease who required supplemental oxygen, according to an NEJM-published study.
Read More